Five Prime Therapeutics Inc. will eliminate 70 jobs while undergoing a restructuring to extend the company’s cash runway.
Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).
GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.
The EMA recommended approving Vitrakvi to tackle tumors with a specific genetic mutation regardless of where the disease started.
Two weeks after the U.S. FDA rejected Acer Therapeutics’ New Drug Application for Edsivo (celiprolol), the company initiated a restructuring plan that includes the elimination of 29 employees.
During an investors’ day conference, Merck Chief Commercial Officer Frank Clyburn pointed to the growth opportunities ahead of the company in oncology due to the strength of three medications.
Johnson & Johnson expects to file marketing applications for at least 10 new drugs between 2019 to 2023, to strengthen the company’s pharma unit which has been a major growth driver.
Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.
GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data
Analysts, Business, Clinical Data, Endometrial Cancer, Fast Track Designation, FDA, Immunotherapies, Influenza, Multiple myeloma, Oncology, Ovarian Cancer, PARP Inhibitors, Pneumonia, Product Pipeline, Quarterly results, R&D, Respiratory Syncytial Virus, VaccinesIn GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.
Eli Lilly and Company and Loxo Oncology Inc. announced a definitive agreement for Lilly to acquire Loxo for $235.00 per share in cash, or approximately $8.0 billion.
